https://www.selleckchem.com/pr....oducts/donafenib-sor
The latter is scheduled for clinical evaluation.Objective This study aimed to examine patient accessibility to new anticancer drugs including reimbursement coverage, time to listing, and listing price during the recent 3 years after the introduction of alternative pricing and reimbursement pathways in South Korea. Methods Anticancer drugs were selected for analysis from the new drugs reviewed from January 2017 to March 2020. Descriptive statistics were used to present the levels of the listing prices. Pearson's correlatio
Like
Comment
Share
